Literature DB >> 15499045

Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Carlos Iribarren1, Myron D Gross, Jeanne A Darbinian, David R Jacobs, Stephen Sidney, Catherine M Loria.   

Abstract

OBJECTIVE: To examine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with calcified coronary plaque in young adults. METHODS AND
RESULTS: Nested case-control study among CARDIA participants at the year 15 examination (2000 to 2001, 33 to 45 years old). Cases (n=266) were those with and controls (n=266) those without evidence of calcified coronary plaque by computed tomography matched 1:1 on sex and race. Lp-PLA2 mass and activity were significantly higher in cases (296+/-101 ng/mL and 36.4+/-12.3 nmol/mL per minute) than in controls (267+/-80 ng/mL and 32.9+/-11.8 nmol/mL per minute). In age-adjusted conditional logistic regression, the odds ratio (OR) of calcified coronary plaque per 1 standard deviation (SD) increment was 1.40 (95% CI, 1.17 to 1.67) and 1.39 (95% CI, 1.14 to 1.70) for Lp-PLA2 mass and activity, respectively. After adjusting for multiple covariates including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and C-reactive protein, a statistically significant association remained for Lp-PLA2 mass (OR, 1.28; 95% CI, 1.03 to 1.60) but not for activity (OR, 1.09; 95% CI, 0.84 to 1.42). No evidence was found for interaction between Lp-PLA2 mass or activity with LDL-C as predictors of calcified coronary plaque.
CONCLUSIONS: An independent association of Lp-PLA2 mass with calcified coronary plaque existed in young adults. Therefore, Lp-PLA2 mass may be a useful marker of subclinical cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499045     DOI: 10.1161/01.ATV.0000148322.89911.44

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  36 in total

1.  Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Authors:  Fujun Zhang; Yiping Wang
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

2.  Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Authors:  A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey
Journal:  HIV Med       Date:  2014-03-20       Impact factor: 3.180

3.  Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Authors:  Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

4.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

5.  Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

Authors:  Ghainsom D Kom; Edzard Schwedhelm; Renke Maas; Lydia Schneider; Ralf Benndorf; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-01-03       Impact factor: 4.335

6.  Kidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2).

Authors:  Carmen A Peralta; Ronit Katz; Michael Shlipak; Ruth Dubin; Ian DeBoer; Nancy Jenny; Annette Fitzpatrick; Carol Koro; Bryan Kestenbaum; Joachim Ix; Mark Sarnak; Mary Cushman
Journal:  Am J Nephrol       Date:  2011-11-01       Impact factor: 3.754

Review 7.  Lp-PLA(2) as a marker of cardiovascular diseases.

Authors:  Sabha Bhatti; Abdul Hakeem; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

8.  Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.

Authors:  Ida J Hatoum; Frank B Hu; Jeanenne J Nelson; Eric B Rimm
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

9.  Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Aramesh Saremi; Thomas E Moritz; Robert J Anderson; Carlos Abraira; William C Duckworth; Peter D Reaven
Journal:  Diabetes Care       Date:  2010-08-31       Impact factor: 19.112

10.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.